Subacromial decompression vs Placebo (sham/placebo device)
Subacromial decompression showed no clear difference in adverse events compared with placebo surgery (moderate certainty).
- RR 0.91 [0.31, 2.65]2 studies · 406 participantsModerate
Subacromial decompression showed no clear difference in adverse events compared with placebo surgery (moderate certainty).
Subacromial decompression showed no clear difference in global assessment of treatment success compared with exercises (low certainty).
The review found no eligible studies for this question.
Other adverse events in people taking macrolide antibiotics showed no clear difference in deaths compared with placebo (low certainty).
It is very uncertain whether other adverse events in people taking macrolide antibiotics changes cardiac disorders compared with placebo (very low certainty).
Other adverse events in people taking macrolide antibiotics showed no clear difference in hearing loss compared with placebo (low certainty).
Other adverse events in people taking macrolide antibiotics may leads to higher taste disturbance compared with placebo (low certainty).
It is very uncertain whether other adverse events in people taking macrolide antibiotics changes hepatobiliary disorders compared with placebo (very low certainty).
Macrolides showed no clear difference in resolution of symptoms post‐treatment (ITT analysis) compared with penicillin (low certainty).
Macrolides showed no clear difference in resolution of symptoms post‐treatment (evaluable participants) compared with penicillin (low certainty).
Macrolides showed no clear difference in incidence of relapse (evaluable participants) compared with penicillin (low certainty).
Macrolides showed no clear difference in adverse events (ITT analysis) compared with penicillin (low certainty).
Tacrolimus showed no clear difference in treatment response at 6 months: complete remission compared with cyclosporin (low certainty).
Tacrolimus showed no clear difference in treatment response at 6 months: complete and partial remission compared with cyclosporin (low certainty).
Tacrolimus showed no clear difference in treatment response at 12 months: complete remission compared with cyclosporin (low certainty).
Tacrolimus showed no clear difference in adverse events: persistent nephrotoxicity compared with cyclosporin (low certainty).